Health
First-in-human study with novel antisense oligonucleotide proves promising – Medical Xpress
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarcti…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics.
“Based on documented, promising therapeutic potential, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a f…
-
General20 hours agoTrump considering ‘world tariff’ of 15-20 per cent
-
General23 hours agoKim Jong Un’s sister Kim Yo Jong rejects peace overtures made by South Korea
-
Business17 hours agoThis ASX dividend stock could be primed for a rebound
-
Noosa News19 hours agoThe First Trailer for ‘Avatar: Fire and Ash’ Takes James Cameron’s Franchise Into Blazing New Terrain